-
Omics, Methylation, AI-Driven Discovery, Online Education: News and Products for February
Mar 08 | Bio-IT World | New products and company updates from around Bio-IT including Seven Bridges’ partnership with Pfizer, Illumina’s Russian approval, new methylation detection platform from Twist, and more. More -
Nanotechnology-Based Vaccine Candidate, Blood Type A Raises Risk, Neanderthal-Derived Protein Offers Protection: COVID-19 Updates
Mar 05 | Bio-IT World I Variant that emerged in the UK could be more transmissible, SARS-CoV-2 may be particularly attracted to blood group A respiratory cells, a balanced T cell response is key to clearing virus without symptoms, and out-of-place large bone marrow cells responsible for brain fog. Plus: Heart muscle cells a target and could lead to cell death, interfere with heart muscle contraction and MIS-C patients have highly activated immune systems that are similar to adult COVID-19 patients. More -
Spatial Surge: AGBT Updates On Single-Cell and Spatial Genomics, In Situ Analysis, More
Mar 04 | Bio-IT World | A host of sponsors and vendor companies attended the virtual AGBT General Meeting this week. Through sponsored talks and even more poster sessions, vendor companies shared their latest work and technology developments and made product announcements. More -
CRISPR For COVID-19: Approaches To Speeding Therapeutic Discovery
Mar 03 | Bio-IT World | Neville Sanjana from the New York Genome Center and NYU turned his attention to COVID-19 early in the pandemic. For several years, his lab has focused on using CRISPR to identify which regions of the genome drive disease. Last year, he applied that expertise to using genome-wide CRISPR screens to look for COVID-19 risk factors. More -
Building A Telomere-to-Telomere Human Pangenome Reference
Mar 02 | Bio-IT World | Our current version of the human reference genome does not adequately represent genetic diversity in the human population, Karen Miga told the virtual audience at this week’s AGBT General Meeting. The Human Pangenome Reference Consortium and the Telomere-to-Telomere Consortium are working to change that. More -
Updates To All of Us, First Genomic Results Returned To Participants
Mar 01 | Bio-IT World | Josh Denny, CEO of NIH’s All of Us program, gave an update on the population sequencing program in the opening session of the virtual AGBT General Meeting this week. More -
More Immunological Updates for SARS-CoV-2 Infection, Modeling New Drugs: COVID-19 Updates
Feb 26 | Bio-IT World | More insights into how the immune system reacts to SARS-CoV-2 infection, docking analysis predicts new COVID-19 drugs, and impacts of temperature and humidity. Plus: correlating COVID-19 symptoms and genetic profiles. More -
Linus’ Law: What greater collaboration could do for scientific research
Feb 25 | Bio-IT World | Having spent the last decade with one foot in the door of the scientific research world, and the other foot in the door of the software world, I have viscerally experienced a fundamental flaw in how scientific research is done today: collaboration among scientists is severely lacking. More -
African Centers of Excellence in Bioinformatics and Data-Intensive Sciences: Building The Technology Foundations For Global Growth
Feb 23 | Bio-IT World | Information technology has become a fundamental research tool for the international biomedical research community. That’s why NIAID has been building the African Centers of Excellence in Bioinformatics and Data-Intensive Science in Mali and Uganda. Equipping scientists in Africa with bioinformatics tools and technologies has come with some unique challenges, but also promises untold returns. More -
Modeling New Drug Options, Better Look At Immune Response, Impact of Chromosome 12: COVID-19 Updates
Feb 19 | Bio-IT World | Specialized cells in a child’s immune system rapidly target SARS-CoV-2, nasal antiviral blocks transmission in ferrets, machine learning used for drug repurposing, insight into how the virus attacks mucus membrane cells, and a CDC update on anaphylaxis after vaccination. Plus: Fauci on known variants of the virus. More


Riffyn’s pioneering cloud system, Riffyn Nexus, delivers 2X faster development cycles and 4X productivity gains to the world’s most advanced scientific R&D organizations. Its process-centric experiment design, data capture, and
data analytics overcome the limitations of ELN and LIMS systems. Its adaptive data integration engine delivers results that are always ready for machine learning.
Read more here!


Digital Therapeutics: Taking digital health to a new level
Benchling is the most widely-adopted life sciences R&D cloud. Accelerate, measure, and forecast R&D – from discovery through bioprocessing – all
in one place. It’s a fully unified platform that centralizes and standardizes all R&D data, so you can spend less time fighting with legacy software, and more time reaching breakthrough discoveries.
Read more here!